Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.37 |
|---|---|
| High | 0.40 |
| Low | 0.37 |
| Bid | 0.3702 |
| Offer | 0.3852 |
| Previous close | 0.381 |
| Average volume | 192.53k |
|---|---|
| Shares outstanding | 24.19m |
| Free float | 14.93m |
| P/E (TTM) | -- |
| Market cap | 9.22m USD |
| EPS (TTM) | -7.14 USD |
Data delayed at least 15 minutes, as of Mar 05 2026 19:08 GMT.
More ▼
- Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
- UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
- Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
- Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics
- Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
- Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
- Renovaro Provides Update to Definitive Agreement with Predictive Oncology
More ▼
